Grifols (GRFS) Non Operating Income (2010 - 2023)
Grifols' (GRFS) quarterly Non Operating Income came in at $618082.3 in Q4 2023, up 36.77% YoY from $451909.4 in Q4 2022, and up 36.77% on a QoQ basis from $451909.4 in Q4 2022.
Grifols (GRFS) Non Operating Income (2010 - 2023) Analysis & Trends
Grifols (GRFS) has 13 years of Non Operating Income data on file, last reported at $618082.3 in Q4 2023.
- Quarterly Non Operating Income rose 36.77% year-over-year to $618082.3 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$311.3 million (up 23.21% YoY) and the FY2025 annual result came in at -$731.0 million, up 8.54% from the prior year.
- Non Operating Income improved to $618082.3 in Q4 2023, from $451909.4 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $618082.3 in Q4 2023 to a low of -$293.8 million in Q4 2019.
- A 4-year average of -$80.9 million and a median of -$18.6 million in 2020 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2019 — Non Operating Income slumped 42.72% — and 2020, when it surged 80.1%.
- Tracing GRFS's Non Operating Income over 4 years: stood at -$293.8 million in 2019, then jumped by 93.67% to -$18.6 million in 2020, then jumped by 102.43% to $451909.4 in 2022, then surged by 36.77% to $618082.3 in 2023.
- The last three Non Operating Income figures came in at $618082.3 (Q4 2023), $451909.4 (Q4 2022), and -$18.6 million (Q1 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -73.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 387.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 618,082.29 |
| Dec 31, 2022 | 451,909.39 |
| Mar 31, 2020 | -18.60 Mn |
| Dec 31, 2019 | -293.75 Mn |
| Mar 31, 2019 | -93.45 Mn |
| Dec 31, 2018 | -205.83 Mn |
| Jun 30, 2018 | 47.30 Mn |
| Mar 31, 2018 | -78.08 Mn |
| Dec 31, 2017 | -242.34 Mn |
| Jun 30, 2017 | 89.46 Mn |
| Mar 31, 2017 | -70.56 Mn |
| Dec 31, 2016 | -54.20 Mn |
| Sep 30, 2016 | 66.11 Mn |
| Jun 30, 2016 | 62.82 Mn |
| Mar 31, 2016 | -75.63 Mn |
| Dec 31, 2015 | -297.97 Mn |
| Sep 30, 2015 | 69.40 Mn |
| Jun 30, 2015 | 67.39 Mn |
| Mar 31, 2015 | 83.89 Mn |
| Dec 31, 2014 | 104.43 Mn |